Thanks for updating us on the clinicaltrial.gov site.
The NIH Phase 1 continues to bring significance to Imetelstat as a future game changer especially since they continue to add sites. Here's why: Big pharma does not engage in pediatric trials unless, of course, the drug is to treat a pediatric malady. It costs too, too much money and besides the pediatric practioners can use an approved drug "off label" so big pharma takes a pass. I was curious about 6 months ago at just how many pediatric trials are being undertaken by the NIH for the pediatric population in cancer. I recall it to be fewer than 5 and Imetelsat was one of them. The medical researchers (ie John Hopkins, Boston children's, etc) wants this drug to be accessible to the pediatric population from the git go. This Phase I, like all Phase I, is to establish dosing protocols and will be completed in 2014. Hopefully Geron's studies won't take until 2014 to get approved.